Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results

2006 ◽  
Vol 2 (1) ◽  
pp. 3-6 ◽  
Author(s):  
Sophie Gad ◽  
Valentine Sultan-Amar ◽  
Jean-Baptiste Meric ◽  
Hassan Izzedine ◽  
David Khayat ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Gene Analysis ◽  
Antiangiogenic Treatment ◽  
Vhl Gene ◽  
Von Hippel Lindau ◽  
Preliminary Results

scholarly journals Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group

2018 ◽  
Vol 16 (4) ◽  
pp. 298-304 ◽  
Author(s):  
Brian I. Rini ◽  
Thomas E. Hutson ◽  
Robert A. Figlin ◽  
Maria Josè Lechuga ◽  
Olga Valota ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Risk Group

Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome

Apmis ◽  
2017 ◽  
Vol 125 (3) ◽  
pp. 259-263 ◽  
Author(s):  
Juan Ruiz-Bañobre ◽  
Ihab Abdulkader ◽  
Urbano Anido ◽  
Luis León ◽  
Rafael López-López ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
De Novo ◽  
Immunohistochemical Analyses

VHL gene mutation and hypermethylation in patients with renal cell carcinoma: Preliminary results and clinical correlation

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 9619-9619
Author(s):  
P. E. Shaheen ◽  
S. A. Vaziri ◽  
R. Ganapathi ◽  
P. Elson ◽  
M. Zhou ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Mutation ◽  
Renal Cell ◽  
Clinical Correlation ◽  
Vhl Gene ◽  
Preliminary Results

Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 459-459
Author(s):  
Dong Hoe Koo ◽  
Inkeun Park ◽  
Jae-Lyun Lee ◽  
Jin-Hee Ahn ◽  
Dae Ho Lee ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Metastatic Renal Cell Carcinoma ◽  
Stable Disease ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival

459 Background: The purpose of the this study is to evaluate the clinical outcome of VEGFR-TKIs interruption in patients with metastatic renal cell carcinoma (mRCC) after achieving stable disease (SD) or better response. Methods: A retrospective analysis of medical records and imaging studies was performed on all patients with mRCC treated with VEGFR-TKIs between January 2008 and July 2014 (n=505). Patients who achieved SD or better response under VEGFR-TKI and later discontinued VEGFR-TKIs for any reason with the exception of disease progression were included in the analysis. Outcomes analyzed were progression free survival (PFS) after VEGFR-TKIs discontinuation, patterns of disease progression, time to subsequent therapy (TST), response to VEGFR-TKI resumption, and time to treatment failure (TTF) after TKI resumption. Results: We identified 32 patients (sunitinib=20, sorafenib=7, and pazopanib=5). The responses to VEGFR-TKIs were CR (n=4), PR (n=11), SD (n=15), and controlled but non-measurable (n=2). Median time to interruption from the initiation of VEGFR-TKI therapy was 16.6 months (95% CI, 12.8-20.3). The main causes of VEGFR-TKI interruption was toxicity (n=19, 59.4%), will to have treatment holiday (n=7, 21.8%), patient’s refusal (n=3, 9.4%), and others (n=3, 9.4%). At the time of analysis, 16 patients had disease progression and 1 patient was dead. With a median follow-up duration of 56.6 months (range, 12.6-167.4), median PFS from VEGFR-TKI interruption was 23.8 months (95% CI, 12.5-35.0), and the median TST was 26.2 months (95% CI, 15.9-36.6). The progression was observed in pre-existing lesions in 7 patients (43.7%) or new lesions developed in 9 (56.3%). Among 11 patients who received VEGFR-TKI resumption, 2 patients (18.2%) achieved a PR and the stable disease was observed in 9 (81.8%) with a median TTF of VEGFR-TKI resumption of 6.2 months (95% CI, 4.0-8.4). Conclusions: In patients with mRCC controlled with VEGFR-TKIs, VEGFR-TKI could be interrupted at least temporarily when clinically warranted.

scholarly journals 9º Simpósio Médico Internacional de VHL; III Encontro de Famílias com a Síndrome de VHL Data:

2010 ◽  
Vol 56 (3) ◽  
pp. 395-406
Author(s):  
Instituto Nacional de Câncer José de Alencar Gomes da Silva
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Suppressor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Cell Carcinomas ◽  
Vhl Gene ◽  
Von Hippel Lindau ◽  
Number Variation ◽  
Von Hippel Lindau Disease

Resumos escolhidos para publicação. Nessa edição, os títulos foram: Extramitochondrial Fumarate Inhibits Multiple 2-OG Oxygenases in Fumarate Hydratase Deficient Cells; What is the Best Treatment for Renal Lesions in VHL?; Characterization of the VHL-ECM Pathway; Induction of Extreme Metabolic Depression by the Nucleolus; Mutation of SDHB and Inherited RCC Susceptibility; Metabolic Links to Renal Cancer; Radiosurgery for Cerebellar Hemangioblastomas; Neoplastic Diagnosis Timing Profile in von Hippel-Lindau´s Patients in a Personal Series; Regulation of the VHL Tumor Suppressor; Destructive Targeting via VHL Beyond HIF; Folliculin Functional Studies and Mouse Models of Birt-Hogg-Dube’ Syndrome; A Zebrafish Model for VHL; Relief of Intractable Nausea after Resection of Brainstem Hemangioblastoma in Patients with von Hippel-Lindau Disease: a Clinical Series; Somatic Alteration of the VHL Gene in Sporadic Renal-Cell Carcinomas as a Potential Biomarker; VHL Tumor Suppressor Protein Regulates Oncogenic Macroautophagy in Renal Clear Cell Carcinoma (RCC); Identification of Germline Mutations in the VHL Gene of Families with the von Hippel-Lindau Disease; Expression Profile in von Hippel-Lindau Disease Associated and Sporadic Clear-Cell Renal Cell Carcinomas; Proposed Changes to the VHL Handbook; Evaluation of the Somatic Alterations of the VHL Gene in Renal Cell Carcinoma Associated with von Hippel-Lindau Disease (VHL); Copy Number Variation Analysis of a Pancreatic Neuroendocrine Tumor (NET) from a Patient with von Hippel-Lindau (VHL); Molecular Dynamics Study of the Mutant pVHL Phe76del and its Interactions with Components of the pVHL Complex; Genomic Copy Number Variation Analysis in VHL-Associated Renal Cell Carcinomas Suggests Clonality; Management of Brainstem and Spinal cord Hemangioblastomas in Patients with von Hippel-Lindau Disease; The Benefits of Ultrasound in Resection of CNS Hemangioblastomas; Management of Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease; Neuronal Differentiation of Stem cells by Transfer of a VHL Peptide and Regenerative Therapy; Endolymphatic Sac Tumors (ELST) in VHL Patients - Evaluation of Screening Methods in a National Study; Delineating Genotype-Phenotype Correlations Among Brazilian Families with von Hippel-Lindau Disease; Endothelial Fenestrations Associated with VHL Gene Alteration is a Potent Target of Anti-VEGF Therap; Role of Pregnancy on Hemangioblastomas in von Hippel-Lindau Disease: a Retrospective French Study; An Evaluation of the Danish National Clinical Guidelines for Von Hippel-Lindau (VHL); Vitreoretinal Surgery for Severe Retinal Capillary Hemangiomas; Oncololytic Targeting of Renal Cell Carcinoma via Encephalomyocarditis Virus; Emerging Therapeutic Options for VHL Patients: a Tale of three Studies; Altering the Stability of Mutant VHL: Potential Therapeutic Consequences; Tale of the Tail: Clinical and Functional Properties of Novel VHL Mutation (X214L) Consistent with Type 2A Phenotype and Low Risk of Renal Cell Carcinoma; Knife for Intracranial Hemangioblastomas in von Hippel-Lindau Patients. When and How?; VHL in Brazil: Genetics, Biobanking and VHL Family Care; Understanding VHL Disease: Molecular Characterization of a Spanish Series; Case Report: Radiosurgery for Endolymphatic Sac Tumor in a Patient with von Hippel-Lindau Disease; Primary Cilium: a Tumor Suppressor Organelle.

scholarly journals Preliminary Results of Early Assessment of Response with Perfusion-CT in Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib

2012 ◽  
Vol 23 ◽  
pp. ix282-ix283
Author(s):  
O. Reig Torras ◽  
M.C. Sebastia ◽  
I. Victoria ◽  
B. Paño ◽  
M. Campayo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Perfusion Ct ◽  
Early Assessment ◽  
Preliminary Results

scholarly journals Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

In Vivo ◽  
2020 ◽  
Vol 34 (5) ◽  
pp. 2647-2652
Author(s):  
KAZUO KOBAYASHI ◽  
YUSUKE IIKURA ◽  
MAKOTO HIRAIDE ◽  
TAKASHI YOKOKAWA ◽  
TAKESHI AOYAMA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Outcome ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell
Sign in / Sign up

Export Citation Format

Share Document